Published in AIDS Weekly, April 19th, 2010
"AID-mediated SHM in B cell lines can be used to generate patient's HIV-1 envelope protein diversity in vitro for subsequent vaccination of HIV-1-infected patient at the beginning of asymptomatic period with a resulting mixture of mutant envelope proteins," wrote K.V. Suslov and colleagues.
The researchers concluded: "Suggested approach, which represents a vaccination against R5-X4 HIV-1 switching, might open possibilities for creation of patient-specific therapeutic HIV vaccines based on induction of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.